A comparison of tepoxalin-buprenorphine combination and buprenorphine for postoperative analgesia in dogs: a clinical study.
The present study compares the analgesic effect of a tepoxalin-buprenorphine combination to that of buprenorphine alone in the 24 h peri-operative period in 20 dogs undergoing cranial cruciate ligament repair, which were randomly assigned to the two treatment protocols (n = 10). Additionally, possible side effects induced by tepoxalin were investigated. Analgesia was compared using a visual analogue scale (VAS) and a multifactorial pain scale (MFPS), by an anaesthetist blinded from treatment. Analysis of the overall VAS-scores showed a significant decrease over time in both treatment groups. The decrease in the two groups was not significantly different from each other. No significant differences were found between the MFPS-scores of both protocols. Potential side effects of tepoxalin were investigated by venous blood sampling before premedication and 24 h after extubation, a buccal mucosal bleeding time test and recording of vomiting, diarrhoea and adverse effects at the surgical site. Analysis of the blood parameters showed that fibrinogen levels were overall higher 24 h after surgery in both protocols, but were significantly more elevated in the tepoxalin group. No significant differences were found for the other blood parameters. Statistically, tepoxalin failed to improve analgesia induced by buprenorphine. There was no convincing evidence that the administration of tepoxalin was not associated with gastrointestinal side effects. There were no significant adverse effects on renal function and primary haemostasis.
Bosmans
T
T
Department of Small Animal Medicine and Clinical Biology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium. tim.bosmans@ugent.be
Gasthuys
F
F
Duchateau
L
L
de Bruin
T
T
Verhoeven
G
G
Polis
I
I
D000701:Analgesics, Opioid / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D016118:Anterior Cruciate Ligament / Q000601:surgery; D000070598:Anterior Cruciate Ligament Injuries; D002047:Buprenorphine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004285:Dogs; D004359:Drug Therapy, Combination; D005260:Female; D008297:Male; D010147:Pain Measurement / Q000662:veterinary; D010149:Postoperative Pain / Q000188:drug therapy / Q000662:veterinary*; D011182:Postoperative Care / Q000379:methods / Q000662:veterinary; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D011720:Pyrazoles; D002047:Buprenorphine; C073135:tepoxalin